Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | MG 98 |
Synonyms | |
Therapy Description |
MG 98 is an oligonucleotide antisense that inhibits DNMT1, thereby resulting in altered expression of DNMT1 targeted genes due to decreased methylation and thus, potentially resulting in tumor growth inhibition (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MG 98 | MG98|MG-98 | DNMT1 inhibitor 3 | MG 98 is an oligonucleotide antisense that inhibits DNMT1, thereby resulting in altered expression of DNMT1 targeted genes due to decreased methylation and thus, potentially resulting in tumor growth inhibition (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | renal carcinoma | no benefit | MG 98 | Phase II | Actionable | In a Phase II trial, MG 98 treatment in seventeen evaluable patients resulted in stable disease in six patients, progressive disease in nine patients, and no objective responses, and the trial was terminated early due to a lack of responses (PMID: 16502349). | 16502349 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|